All patients
corticosteroids: no corticosteroids: yes critical disease severe disease
Immunosuppressants drugs in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Amra, 2021 0.47 [0.12; 1.93]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
1.08 [0.48 ; 2.46 ] Amra, 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, Talaschian, 2021, Veiga, 2021 4 44% 308 moderate not evaluable deathsdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
Hamed, 2021 1.83 [0.16; 21.66]
Kumar, 2021 0.06 [0.00; 1.35]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.80 [0.53 ; 1.23 ] CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, Hamed, 2021, Kumar, 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, Talaschian, 2021, Veiga, 2021 8 33% 1,659 moderate not evaluable deaths (time to event analysis only)detailed results Talaschian, 2021 1.25 [0.30; 5.14]
1.25 [0.30 ; 5.14 ] Talaschian, 2021 1 0% 40 NA not evaluable clinical deteriorationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
0.56 [0.26 ; 1.20 ] CORIMUNO-TOCI-1 (Group 1), 2020 1 0% 130 NA not evaluable clinical improvementdetailed results REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
REMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78]
1.67 [1.32 ; 2.11 ] REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021 2 0% 1,205 moderate not evaluable clinical improvement (14-day)detailed results REMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87]
1.86 [1.20 ; 2.87 ] REMAP-CAP sarilumab, 2021 1 0% 450 NA not evaluable death or ventilationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
Veiga, 2021 1.54 [0.65; 3.63]
0.93 [0.35 ; 2.49 ] CORIMUNO-TOCI-1 (Group 1), 2020, Veiga, 2021 2 63% 260 moderate not evaluable mechanical ventilationdetailed results Hamed, 2021 3.15 [0.57; 17.48]
3.15 [0.57 ; 17.48 ] Hamed, 2021 1 0% 49 NA not evaluable ICU admissiondetailed results Hamed, 2021 3.15 [0.57; 17.48]
3.15 [0.57 ; 17.48 ] Hamed, 2021 1 0% 49 NA not evaluable recoverydetailed results Talaschian, 2021 0.64 [0.14; 2.92]
0.64 [0.14 ; 2.92 ] Talaschian, 2021 1 0% 36 NA not evaluable serious adverse eventsdetailed results Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.94 [0.74 ; 5.09 ] Talaschian, 2021, Veiga, 2021 2 0% 165 moderate not evaluable adverse eventsdetailed results Veiga, 2021 1.65 [0.81; 3.37]
1.65 [0.81 ; 3.37 ] Veiga, 2021 1 0% 129 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-02 22:54 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 91
- treatments: 596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526
- roots T: 290
